General
Preferred name
PERAMPANEL
Synonyms
E-2007 ()
ER-155055-90 ()
Fycompa ()
E2007 ()
Perampanel (exempt preparation) ()
P&D ID
PD012733
CAS
380917-97-5
1174302-51-2
Tags
available
drug
Approved by
PMDA
FDA
EMA
First approval
2012
Drug indication
Parkinson disease
Epilepsy
Diabetic neuropathy
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Perampanel is an anticonvulsant. The drug is administered as perampanel hydrate.
It is first and only FDA-approved non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist. (GtoPdb)
Compound Sets
14
Cayman Chemical Bioactives
43518
23003
ChEMBL Approved Drugs
CHEMBL1214124
ChEMBL Drugs
CHEMBL1214124
DrugBank
DB08883
DrugBank Approved Drugs
DB08883
DrugCentral
4684
DrugCentral Approved Drugs
4684
DrugMAP
DMJDYNQ
DrugMAP Approved Drugs
DMJDYNQ
Guide to Pharmacology
7050
Mcule NIBR MoA Box Subset
MCULE-6282665861
NCATS Inxight Approved Drugs
H821664NPK
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
External IDs
33
Properties
(calculated by RDKit )
Molecular Weight
349.12
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
3
Ring Count
4
Aromatic Ring Count
4
cLogP
4.44
TPSA
58.68
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Member status
virtual
MOA
AMPA Antagonists
Source data